Eris Lifesciences
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Eris Lifesciences is navigating a pivotal transition towards a more innovation-driven pharmaceutical model, focusing on biologics and complex injectables. Management's strategic emphasis on expanding its insulin portfolio and launching new products, such as the semaglutide brand Sundae, is expected to enhance revenue growth, particularly in the chronic therapy segment. However, challenges remain, including regulatory compliance costs and supply chain disruptions that may pressure margins in the near term. Vista's financial outlook reflects stable revenue growth and margins, supported by a robust domestic market and a favorable regulatory environment. The anticipated growth in the insulin market, despite current declines in certain segments, positions Eris for potential market share gains. Over the next 12-24 months, key opportunities include the successful commercialization of expanded manufacturing capabilities and the launch of new high-margin products. Conversely, watchpoints include ongoing regulatory scrutiny and the impact of rising input costs on profitability. Overall, Eris is well-positioned for long-term growth, with a target price reflecting an expected upside of approximately 17.3%
Why We Like This Stock
- Expansion into the insulin market with a strong product pipeline, including the semaglutide brand Sundae
- Strategic investments in manufacturing capabilities are expected to enhance operational efficiency and margins
- Resilient domestic demand in chronic therapies supports stable revenue growth
Things To Watch Out For
- Regulatory compliance costs and supply chain disruptions may pressure near-term margins
- Current declines in certain insulin market segments pose challenges for growth
- Increased competition in the domestic market could impact pricing power
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 2,009 | 2,894 | 3,129 | 3,116 | 3,522 |
| Profit Before Tax (Cr.) | 428 | 487 | 656 | 678 | 799 |
| PBT Margin | 21.3% | 16.8% | 21.0% | 21.7% | 22.7% |
| Net Profit (Cr.) | 346 | 375 | 495 | 508 | 565 |
| Earnings Per Share | 24.6 | 25.4 | 33.7 | 34.6 | 40.8 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| HDFC Securities | ▲ Buy | 1,730 | 30-Jul-2026 |
| Morgan Stanley | ► Neutral | 1,425 | 30-Jul-2026 |
| Motilal Oswal | ► Neutral | 1,435 | 30-Jul-2026 |
| Prabhudas Liladhar | ▲ Buy | 1,700 | 30-Jul-2026 |
| Macguire | ▲ Buy | 1,680 | 22-Apr-2026 |
Company Overview
Show Company Profile
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as antidiabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and anti-natal care solutions. It offers its products through wholesale drug distributors, stockists, retail and e-commerce pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is headquartered in Ahmedabad, India.